Should Gleason score 7 prostate cancerbe considered a unique grade category?

Urology

Volumn 53, Issue 2, 1999, Pages 372-377

  Tefilli, Marcos V ^a   Gheiler, Edward L ^a   Tiguert, Rabi ^a   Sakr, Wael ^a   Grignon, David J ^a   Banerjee, Mousumi ^a   Pontes, J Edson ^a   Wood Jr , David P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SCORING SYSTEM;

DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0032893572     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00479-8     Document Type: Article

References (17)

1. Lerner S.E., Blute M.L., Bergstralh E.J., et al. Analysis of risk factors of progression in patients with pathologically confined prostate cancer after radical retropubic prostatectomy. J Urol. 156:1996;137-143.
2. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer Prostate Patients Outcomes Research Team . JAMA. 269:1993;2650-2658.
3. Gleason D.F., Mellinger G.T. The Veterans Administration Cooperative Urological Research Group prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging . J Urol. 111:1974;58-64.
4. Fowler J.E., Mills S.E. Operable prostatic carcinoma correlations among clinical stage, pathological stage, Gleason histological score and early disease-free survival . J Urol. 133:1984;49-52.
5. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 150:1993;110-114.
6. Epstein J.I., Carmichael M., Partin A.W., et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow up. J Urol. 149:1993;1478-1481.
7. Montie J.E. Current prognostic factors for prostate carcinoma. Cancer. 78:1996;341-344.
8. Egawa S., Go M., Kuwao S., et al. Long-term impact of conservative management on localized prostate cancer. Urology. 42:1993;520-526.
9. Walsh P.C., Jewett H.J. Radical surgery for prostate cancer. Cancer. 45:1980;1906-1911.
10. Schroder F.H., Hermanck P., Denis L., et al. The TNM classification of prostate cancer. Prostate. 4:(suppl):1992;129-133.
11. Palken M., Cobb O.E., Warren B.H., et al. Prostate cancer correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volume in radical prostatectomy specimens . J Urol. 143:1990;1155-1162.
12. Epstein J.I., Pound C.R., Partin A.W., et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol. 160:1998;97-101.
13. Ohori M., Goad J.R., Wheeler T.M., et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 152:1994;1843-1849.
14. Oefelein M.G., Smith N.D., Grayhack J.T., et al. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol. 158:1997;1460-1465.
15. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy the John Hopkins experience after 10 years . Urol Clin North Am. 20:1993;713-725.
16. Zagars G.K. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 20:1993;737-747.
17. Sakr W.A., Grignon D.J., Swiriduk M., et al. Gleason score VII prostate cancer: a heterogeneous entity? Correlation with clinicopathologic parameters and biochemical recurrence (abstract). Mod Pathol. 10:1997;88A.